(Q44187033)

English

Outcomes and predictive factors for biochemical relapse following primary androgen deprivation therapy in men with bone scan negative prostate cancer

scientific article published in February 2011

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Outcomes and predictive factors for biochemical relapse following primary androgen deprivation therapy in men with bone scan negative prostate cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

author name string

S Hori

1

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

T Jabbar

2

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

N Kachroo

3

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

J C Vasconcelos

4

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

C N Robson

5

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

V J Gnanapragasam

6

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

publication date

1 February 2011

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Journal of Cancer Research and Clinical Oncology

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

137

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

235-241

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00432-010-0877-9

21 January 2018

National practice patterns and time trends in androgen ablation for localized prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00432-010-0877-9

21 January 2018

Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE).

1 reference

https://api.crossref.org/works/10.1007%2FS00432-010-0877-9

21 January 2018

Survival outcomes in men receiving androgen-deprivation therapy as primary or salvage treatment for localized or advanced prostate cancer: 20-year single-centre experience

1 reference

https://api.crossref.org/works/10.1007%2FS00432-010-0877-9

21 January 2018

Recent trends in prostate cancer incidence and mortality in southeast England

1 reference

https://api.crossref.org/works/10.1007%2FS00432-010-0877-9

21 January 2018

Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162).

1 reference

https://api.crossref.org/works/10.1007%2FS00432-010-0877-9

21 January 2018

Clinical outcomes of androgen deprivation as the sole therapy for localized and locally advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00432-010-0877-9

21 January 2018

Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).

1 reference

https://api.crossref.org/works/10.1007%2FS00432-010-0877-9

21 January 2018

Luteinizing hormone-releasing hormone analogues and hormone ablation for prostate cancer: state of the art.

1 reference

https://api.crossref.org/works/10.1007%2FS00432-010-0877-9

21 January 2018

Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00432-010-0877-9

21 January 2018

Androgen deprivation therapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00432-010-0877-9

21 January 2018

Prognostic factors in patients with advanced prostate cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS00432-010-0877-9

21 January 2018

Prostate specific antigen in diagnosis, staging, and follow-up of prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20390426

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nadir prostate-specific antigen as a predictor of progression to androgen-independent prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20390426

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic significance of the nadir prostate specific antigen level after hormone therapy for prostate cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20390426

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20390426

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Usefulness of prostate-specific antigen nadir as predictor of androgen-independent progression of metastatic prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20390426

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy of primary hormone therapy for localized or locally advanced prostate cancer: results of a 10-year follow-up

1 reference

https://pubmed.ncbi.nlm.nih.gov/20390426

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

EAU guidelines on prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20390426

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic factors in survival free of progression after androgen deprivation therapy for treatment of prostate cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20390426

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical predictors of androgen-independent prostate cancer and survival in the prostate-specific antigen era

1 reference

https://pubmed.ncbi.nlm.nih.gov/20390426

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nadir prostate-specific antigen best predicts the progression to androgen-independent prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20390426

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A prognostic index for the clinical management of patients with advanced prostatic cancer: a British Prostate Study Group investigation

1 reference

https://pubmed.ncbi.nlm.nih.gov/20390426

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00432-010-0877-9

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44187033&oldid=2206485344"